<DOC>
	<DOCNO>NCT00768651</DOCNO>
	<brief_summary>We aim study administration medication increase secretion hormone intestine improve glycemic control , reduce insulin use promote β-cell regeneration/expansion subject type 1 diabetes follow islet transplantation back use small dos insulin early graft dysfunction . We believe result enable u understand whether drug could useful islet transplant recipient , particularly glycemic control deteriorate .</brief_summary>
	<brief_title>Incretin Effect Use After Clinical Islet Transplantation</brief_title>
	<detailed_description>This single centre non-randomized pilot study . Subjects recruit current cohort islet transplant recipient University Alberta . The primary objective study evaluate whether combination sitagliptin pantoprazole restore insulin independence previously insulin independent islet transplant recipient experience early graft dysfunction . The study also evaluate safety combination drug therapy .</detailed_description>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion enrol study : 1 . Male female , age 18 70 , inclusive , previous islet transplant recipient ( least 3 month since last islet transplant ) receive transplant University Alberta . 2 . Insulin independent 3 month long islet transplant . 3 . Early graft dysfunction define : 1 . HbA1c &gt; 6 % ( le 7.5 % ) ; 2. fast glucose &gt; 7 mmol/L ( 126 mg/dl ) ; 3. random glucose &gt; 10 mmol/L ( 180 mg/dl ) , 4 . Total insulin use &lt; 10 units/day . 4 . Cpeptide positive . 5 . Able provide inform consent . Subjects meet follow criterion exclude study : 1 . Unable provide inform consent . 2 . Prior therapy sitagliptin proton pump inhibitor precede 2 month . 3 . Vulnerable population ( i.e . cognitively impaired , pregnant woman , reside institution , University Alberta student employee supervision investigator ) . 4 . Children , adolescent patient `` contraindication '' `` warn '' list package insert study drug : 1 . Hypersensitivity sitagliptin pantoprazole component formulation . 2 . Renal disease renal dysfunction ( suggest serum creatinine level ≥ 136 µmol/L ( male ) , ≥ 124 µmol/L ( female ) abnormal creatinine clearance ; estimate Glomerular Filtration Rate ( GFR ) &lt; 50 ml/min/1.73m2 ) . 3 . Acute chronic metabolic acidosis without coma ( include diabetic ketoacidosis ) . 5 . Uncontrolled hyperglycemia 6 . Any subject opinion investigator would good candidate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>